PAVmed Inc. (NASDAQ:PAVM) Short Interest Up 164.6% in December

PAVmed Inc. (NASDAQ:PAVM) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 1,130,869 shares, an increase of 164.6% from the December 15th total of 427,310 shares. Based on an average daily trading volume, of 566,478 shares, the days-to-cover ratio is currently 2.0 days. Currently, 125.2% of the shares of the company are short sold. Currently, 125.2% of the shares of the company are short sold. Based on an average daily trading volume, of 566,478 shares, the days-to-cover ratio is currently 2.0 days.

PAVmed Price Performance

PAVM opened at $8.29 on Wednesday. The business has a 50 day simple moving average of $9.51 and a 200-day simple moving average of $12.89. The stock has a market capitalization of $8.21 million, a P/E ratio of -0.48 and a beta of 1.10. PAVmed has a 12 month low of $6.00 and a 12 month high of $26.85.

Institutional Investors Weigh In On PAVmed

A hedge fund recently raised its stake in PAVmed stock. Jane Street Group LLC lifted its stake in shares of PAVmed Inc. (NASDAQ:PAVM) by 392.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 52,676 shares of the company’s stock after purchasing an additional 41,990 shares during the quarter. Jane Street Group LLC owned about 0.31% of PAVmed worth $32,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 19.93% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on PAVM shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of PAVmed in a research note on Wednesday, October 8th. Zacks Research cut PAVmed from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 24th. Finally, Ascendiant Capital Markets decreased their price target on PAVmed from $600.00 to $510.00 and set a “buy” rating for the company in a report on Wednesday, December 10th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, PAVmed presently has a consensus rating of “Hold” and an average price target of $510.00.

PAVmed Company Profile

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.